Pharma Mar (PHM) Stock Overview
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PHM from our risk checks.
PHM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pharma Mar, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €76.35 |
| 52 Week High | €105.80 |
| 52 Week Low | €70.60 |
| Beta | 0.35 |
| 1 Month Change | 0.46% |
| 3 Month Change | -12.79% |
| 1 Year Change | -3.29% |
| 3 Year Change | 21.23% |
| 5 Year Change | n/a |
| Change since IPO | 12.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHM | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 1.6% | -1.4% | 1.4% |
| 1Y | -3.3% | 13.7% | 38.8% |
Return vs Industry: PHM underperformed the Austrian Biotechs industry which returned 14.6% over the past year.
Return vs Market: PHM underperformed the Austrian Market which returned 37.7% over the past year.
Price Volatility
| PHM volatility | |
|---|---|
| PHM Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in AT Market | 5.2% |
| 10% least volatile stocks in AT Market | 2.1% |
Stable Share Price: PHM has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: PHM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 500 | Jose Fernandez Sousa-Faro | www.pharmamar.com |
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin that is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca, a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma.
Pharma Mar, S.A. Fundamentals Summary
| PHM fundamental statistics | |
|---|---|
| Market cap | €1.32b |
| Earnings (TTM) | €34.01m |
| Revenue (TTM) | €179.28m |
Is PHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHM income statement (TTM) | |
|---|---|
| Revenue | €179.28m |
| Cost of Revenue | €9.80m |
| Gross Profit | €169.48m |
| Other Expenses | €135.47m |
| Earnings | €34.01m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.98 |
| Gross Margin | 94.53% |
| Net Profit Margin | 18.97% |
| Debt/Equity Ratio | 24.1% |
How did PHM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 03:40 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharma Mar, S.A. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guilherme Sampaio | Banco BPI, S.A. |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Keay Nakae | Chardan Capital Markets, LLC |